HilleVax
Clinical-stage biopharmaceutical company developing vaccines for norovirus and other infectious diseases. Publicly traded on NASDAQ (HLVX).
Notes
HilleVax is a clinical-stage biopharmaceutical company focused on developing vaccines against important viral diseases. The company's lead program HIL-214 is a vaccine candidate for norovirus, a highly contagious virus that causes gastroenteritis affecting millions of people annually worldwide.
HIL-214 is a virus-like particle (VLP) vaccine licensed from Takeda Pharmaceutical Company. The vaccine was originally developed by Ligocyte Pharmaceuticals, then acquired by Takeda, before being licensed to HilleVax for further development.
HilleVax went public on NASDAQ (ticker: HLVX) in 2022 and is advancing HIL-214 through clinical development. Norovirus causes an estimated 200,000 deaths annually, primarily in children in developing countries and elderly individuals.
Team
- Sean Tucker, Ph.D. - CEO
- LinkedIn: linkedin.com/in/seantucker
- Experienced team in vaccine development
Additional Research Findings
- Founded in 2019, headquartered in Cambridge, MA
- Public company on NASDAQ (ticker: HLVX) since 2022
- Lead program HIL-214 for norovirus vaccine
- Licensed from Takeda Pharmaceutical
- Virus-like particle (VLP) vaccine platform
- Norovirus causes 200,000+ deaths annually globally
- Clinical trials ongoing
- Backed by leading healthcare investors pre-IPO
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |